Apimeds Pharmaceuticals US, Inc (APUS) financial statements and ratios from SEC XBRL: revenue $107595.00 (TTM), net margin -5577.5%, revenue growth 3710.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $107595.00 |
| Net Margin | -5577.5% |
| Return on Equity | -54.6% |
| Debt / Equity | 0.00 |
| Current Ratio | 0.51 |
| Revenue Growth (YoY) | 3710.0% |
| EPS Growth (YoY) | 205.6% |
| Price / Book | 0.07 |
| Price / Sales | 98.99 |
| FCF Yield | -220.1% |
| Altman Z-Score | 3.27 (safe) |
| Sector P/E (Healthcare) | 21.7 |
APUS overview · APUS earnings · APUS KPIs · APUS investor relations · APUS ownership · APUS peers · APUS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.